Alnylam Reports Q2 Earnings Beat, Raises Revenue Guidance

Alnylam Pharmaceuticals reported Q2 EPS of 32 cents, beating the consensus estimate of 15 cents. The company's Q2 revenue was $773.69M, exceeding the consensus estimate of $662.45M. Alnylam's CEO, Yvonne Greenstreet, stated that the results highlight the company's ability to deliver innovative medicines and advance its pipeline of RNAi therapeutics. The company raised its total net product revenue guidance range by 27% at the midpoint, driven by an upward revision to its TTR franchise revenue guidance.

Alnylam Pharmaceuticals (ALNY) reported its second-quarter 2025 earnings on July 31, 2025, with strong revenue growth and an adjusted EPS that beat analyst expectations. The company's net product revenue for the quarter reached $773.69 million, a 64% year-over-year increase, surpassing the consensus estimate of $656.80 million [1]. Alnylam's adjusted EPS of $0.32 also exceeded the consensus estimate of $0.77 [1].

The company's CEO, Yvonne L. Greenstreet, highlighted the significant progress in delivering innovative medicines and advancing the company's pipeline of RNAi therapeutics. She noted that the strong performance of AMVUTTRA for ATTR-CM contributed to a 77% growth in TTR revenues [1]. Alnylam has also received regulatory approvals for AMVUTTRA in the EU, Brazil, UK, and Japan, further supporting revenue growth [1, 3].

In addition to the strong quarterly performance, Alnylam raised its total net product revenue guidance for 2025 to a range of $2.65 billion to $2.8 billion, up from the initial range of $2.05 billion to $2.25 billion [1, 3]. The company also increased its TTR franchise net revenue guidance to a range of $2.175 billion to $2.275 billion [1, 3]. This upward revision reflects the company's confidence in the commercial success of its products and the potential for further growth in the ATTR-CM market.

The company's stock price surged by 12.07% during the latest trading day following the earnings release [2]. Despite the revenue growth and adjusted EPS beat, Alnylam continues to face challenges in achieving profitability, as reflected in the widening net loss of $-66.28 million for the quarter [2]. However, the company's strategic focus on sustainable growth through innovation and a robust pipeline of investigational RNAi therapeutics positions it well for future success.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX30001E:0-alnylam-pharmaceuticals-q2-revenue-beats-estimates-raises-2025-guidance/
[2] https://www.ainvest.com/news/alnylam-pharmaceuticals-2025-q2-earnings-misses-targets-net-loss-widens-292-2508/
[3] https://investors.alnylam.com/press-release?id=29136